Promising combo aims to wipe out leukemia cells in younger patients

NCT ID NCT02251548

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests a new drug, ibrutinib, added to standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL). The goal is to see if this combination can clear all signs of leukemia from the bone marrow (called MRD-negative complete response). About 85 participants will receive the treatment and be followed for up to 2 years after stopping ibrutinib to check for lasting remission.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA LEUKEMIA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Miami Sylvester Comprehensive Cancer Center

Coral Gables, Florida, 33146, United States
University of Miami Sylvester Comprehensive Cancer Center

Deerfield Beach, Florida, 33442, United States
Unversity of Miami Sylvester Comprehensve Cancer Center

Miami, Florida, 33136, United States
West Michigan Cancer Center

Kalamazoo, Michigan, 49007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.